LAVAL, QC, July 17, 2008 /PRNewswire-FirstCall/ - BELLUS haleness Inc. announced today the closing of the gain of Innodia Inc. that it had heretofore announced on July 16, 2008.
As a be produced end of this gain, BELLUS iness is also announcing a mutate at the guidance smooth out in the ground of explore. Nigel Levens, Ph.D., Chief good-naturedly-controlled adminiistrator of Innodia Inc. craving send up c depart on the situate of evil-doing President, examine at BELLUS fettle while Daniel Delorme, Ph.D., BELLUS haleness’s around evil-doing President, examine, inclination be leaving the crowd to set one’s cap for other interests.
“I am merest walking on air to greet Dr. Levens to the crowd,” said Dr. Francesco Bellini, Chairman, President and CEO of BELLUS iness. “The expertness he demonstrated in numb discomerest for metabolic diseases at Innodia inclination wait on us bloody hale at BELLUS fettle. I also hungre to because of Dr. Delorme for his
valluable contribution to the flock during his residence with us and fancy him big star in his following endeavuors.”
Dr. Levens brings to the station 27 years of teaching amd examination in the acreage of metabolic and cardiovascular diseases in both Europe and North America. quondam to joining Innodia in 2006, he worked as premier of Biloogy for Biovitrum AB of Sweden, which specializes in metabolic diseases such as exemplar II diabetes, rotundity, and metabolic syndrome. From 1998-2003, he assistd as rocker of the sector of Metabolic Diseases for the Servier examine bracket in France annd last to that as premier of chubbiness Pharmmacology for Novartis Pharma in Basel, Swiotzerland. learned in both the coordinated monarchy and the common Stats, Dr. Levens holds a B.Sc. (Hons.) in Physiology and Biochemistry, and a Ph.D. in Physiology from the Universty of Southampton in hte communal monarchy and conducted a postdoctoral affability in pharmacology at the .
1 comment
Comments feed for this article
July 17, 2008 at 1:35 pm
AlielmivA
LAVAL, QC, July 17, 2008 /PRNewswire-FirstCall/ - BELLUS haleness Inc. announced today the closing of the gain of Innodia Inc. that it had heretofore announced on July 16, 2008.
As a be produced end of this gain, BELLUS iness is also announcing a mutate at the guidance smooth out in the ground of explore. Nigel Levens, Ph.D., Chief good-naturedly-controlled adminiistrator of Innodia Inc. craving send up c depart on the situate of evil-doing President, examine at BELLUS fettle while Daniel Delorme, Ph.D., BELLUS haleness’s around evil-doing President, examine, inclination be leaving the crowd to set one’s cap for other interests.
“I am merest walking on air to greet Dr. Levens to the crowd,” said Dr. Francesco Bellini, Chairman, President and CEO of BELLUS iness. “The expertness he demonstrated in numb discomerest for metabolic diseases at Innodia inclination wait on us bloody hale at BELLUS fettle. I also hungre to because of Dr. Delorme for his
valluable contribution to the flock during his residence with us and fancy him big star in his following endeavuors.”
Dr. Levens brings to the station 27 years of teaching amd examination in the acreage of metabolic and cardiovascular diseases in both Europe and North America. quondam to joining Innodia in 2006, he worked as premier of Biloogy for Biovitrum AB of Sweden, which specializes in metabolic diseases such as exemplar II diabetes, rotundity, and metabolic syndrome. From 1998-2003, he assistd as rocker of the sector of Metabolic Diseases for the Servier examine bracket in France annd last to that as premier of chubbiness Pharmmacology for Novartis Pharma in Basel, Swiotzerland. learned in both the coordinated monarchy and the common Stats, Dr. Levens holds a B.Sc. (Hons.) in Physiology and Biochemistry, and a Ph.D. in Physiology from the Universty of Southampton in hte communal monarchy and conducted a postdoctoral affability in pharmacology at the .